Aspirin for primary prevention of cardiovascular disease: a review of recent literature and updated guideline recommendations.
Level 5 - mechanism / opinion, no new human data
Narrative literature review summarizing clinical trials and practice guidelines
PubMed 32924644 · doi:10.1080/14656566.2020.1817389
What was done
The authors reviewed randomized controlled clinical trials and clinical practice guidelines published between July 1, 2016, and April 1, 2019, identified via PubMed, evaluating the efficacy and safety of aspirin for the primary prevention of atherosclerotic cardiovascular disease (ASCVD). They synthesized findings in relation to updated 2019 American College of Cardiology/American Heart Association (ACC/AHA) recommendations.
What was found
The abstract reports no numerical effect sizes or event rates. It reports that recent clinical trials demonstrated an increased risk of bleeding that often outweighed cardiovascular risk reduction. Based on these trials, updated ACC/AHA guidelines recommend limiting primary prevention aspirin therapy to individuals aged 40–70 years with high ASCVD risk and low bleeding risk who cannot adequately control modifiable risk factors.
Why it matters
This review highlights the major clinical shift away from broad, routine aspirin use for primary cardiovascular prevention toward highly selective use in carefully screened, high-risk patients.
Limits
The abstract reports no quantitative metrics, confidence intervals, sample sizes, or total number of included trials. The search was limited to a single database (PubMed) across a narrow publication window (2016–2019) without formal systematic review or meta-analytic pooling methods described.
Cited by
- context Standard clinical guidelines recommend against initiating or continuing aspirin for primary prevention once patients reach their 80s due to increased bleeding risk.